[Modern policy of anti-helicobacter therapy of ulcer disease].
Ryss
E S
ES
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D012189:Retrospective Studies; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists
Sovremennaia taktika antigelikobakternoĭ terapii iazvennoĭ bolezni.